Home › NCT06569212
Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
RecruitingPhase 4
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * \>18 years of age * Neuro-imaging confirmed non-traumatic subarachnoid hemorrhage Exclusion Criteria: * Traumatic cause of subarachnoid hemorrhage (e.g. fall, motor vehicle accident, other blunt trauma) as this is a different mechanism of hemorrhage. * Other forms of traumatic or non-traumatic intracranial bleed including intracerebral hemorrhage (ICH), subdural hemorrhage, epidural hemorrhage * Pregnancy (as the study medication, metoprolol, has FDA Pregnancy Category C rating) * Unstable vital signs not amenable to beta-1 adrenergic receptor inhibitor (B1ARi) administration including: * Systolic blood pressure \< 80 mmHg not stabilized on vasopressor medications * Heart rate \< 50 bpm associated with hypotension * Patients requiring vasopressor agents due to hypotension (SBP \<80 mmHg) * Other vital sign exclusion at the discretion of the treatment team * Previous history of severe heart failure (Stage C or D Heart Failure and/or NYHA Class III or IV) * Patient or legally authorized representative unwilling to provide informed consent
About the study
To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).
What is being tested
- Metoprolol (drug)
- Placebo (drug)
Sponsor: Madeleine Puissant · Participants: 20 · Started: Sep 23, 2024
Contact the study team
- Madeleine Puissant, MD, PhD · Phone: 2076613660
Official record on ClinicalTrials.gov — NCT06569212
Locations in the U.S.
| Maine | MaineHealth, Portland |
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.